# Tepotinib Hepatic Impairment Trial

> **NCT03546608** · PHASE1 · COMPLETED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Tepotinib

## Key facts

- **NCT ID:** NCT03546608
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-13
- **Primary completion:** 2019-02-05
- **Final completion:** 2019-02-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03546608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03546608, "Tepotinib Hepatic Impairment Trial". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03546608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*